Drug Trial Radar · NCT00409175
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Last checked: Nov 20, 2026Latest source record: Dec 17, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Jan 2007
Primary completion
May 2009
Study completion May 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP). Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP. The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience. This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.
Conditions
- Familial Amyloid Polyneuropathy
Interventions
Fx-1006ADrug
Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
PlaceboDrug
Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18Time frame: Month 18
- Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18Time frame: Baseline, Month 18
Locations
10 sites in 9 countries. Site status is shown where the registry gives one.
MGH Neuropathy Laboratory
Boston, Massachusetts
FLENI-Hepatology and Organ Transplant Dept.
Ciudad de Buenos Aires, Buenos Aires, Argentina
Hospital Universitário Prof. Clementino Fraga Filho-UFRJ
Rio de Janeiro, Southeast, Brazil
CHU de Bicetre
Le Kremlin-Bicêtre, Île-de-France Region, France
Universitatsklinikum Munster, Transplant Hepatology
Münster, North Rhine-Westphalia, Germany
Serviço de Neurologia-Hospital de Santa Maria
Lisbon, Lisbon District, Portugal
Unidade Clinica de Paramiloidose-Hospital Santo Antonio
Porto, Norte, Portugal
Hospital Clinic de Barcelona
Barcelona, Catalonia, Spain
Umea University Hospital
Umeå, Västerbotten County, Sweden
Kings College Hospital
London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.